Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression
This machine-learning study (n=17) was able to predict the therapeutic effectiveness of psilocybin for treatment-resistant depression using an algorithm applied to natural speech data from the baseline interviews. The results were 85% accurate and 75% precise.
Authors
- Robin Carhart-Harris
- David Nutt
- Michael Ashton
Published
Abstract
Background
Natural speech analytics has seen some improvements over recent years, and this has opened a window for objective and quantitative diagnosis in psychiatry. Here, we used a machine-learning algorithm applied to natural speech to ask whether language properties measured before psilocybin for treatment-resistant can predict for which patients it will be effective and for which it will not.
Methods
A baseline autobiographical memory interview was conducted and transcribed. Patients with treatment-resistant depression received 2 doses of psilocybin, 10 mg and 25 mg, 7 days apart. Psychological support was provided before, during and after all dosing sessions. Quantitative speech measures were applied to the interview data from 17 patients and 18 untreated age-matched healthy control subjects. A machine-learning algorithm was used to classify between controls and patients and predict treatment response.
Results
Speech analytics and machine learning successfully differentiated depressed patients from healthy controls and identified treatment responders from non-responders with a significant level of 85% of accuracy (75% precision).
Conclusions
Automatic natural language analysis was used to predict effective response to treatment with psilocybin, suggesting that these tools offer a highly cost-effective facility for screening individuals for treatment suitability and sensitivity.
Limitations
The sample size was small and replication is required to strengthen inferences on these results.
Research Summary of 'Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression'
Introduction
Quantitative analysis of natural speech has advanced in recent years and is increasingly applied to psychiatric problems. Previous work has used automated measures of speech coherence and emotion to identify conditions such as schizophrenia and mood disorders, and to predict clinical trajectories; these studies indicate that language features can serve as objective diagnostic and prognostic markers. However, it remained unclear whether pre-treatment speech patterns could predict who will respond to psychedelic-assisted therapy for depression. Carrillo and colleagues set out to test whether automated natural language analytics combined with machine learning could predict clinical response to psilocybin in patients with treatment-resistant depression (TRD). The study applied emotional-sentiment measures to autobiographical interview transcripts collected before treatment and used a classifier to distinguish healthy controls from depressed patients and to predict which patients later responded to psilocybin treatment.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Carrillo, F., Sigman, M., Fernández Slezak, D., Ashton, P., Fitzgerald, L., Stroud, J., Nutt, D. J., & Carhart-Harris, R. L. (2018). Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. Journal of Affective Disorders, 230, 84-86. https://doi.org/10.1016/j.jad.2018.01.006
References (1)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)
Cited By (8)
Papers in Blossom that reference this study
Copa, D., Erritzoe, D., Giribaldi, B. et al. · Journal of Affective Disorders (2024)
Tagliazucchi, E. · Frontiers in Pharmacology (2022)
Balaet, M. · Frontiers in Neuroscience (2022)
Cox, D. J., Garcia-Romeu, A., Johnson, M. W. · The American Journal of Drug and Alcohol Abuse (2021)
Romeo, B., Hermand, M., Pétillion, A. et al. · Journal of Psychiatric Research (2021)
Sanz, C., Pallavicini, C., Carrillo, F. et al. · Consciousness and Cognition (2021)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.